PATENTSCOPE: EN_ALL:nmr AND PA:abbvie

MODULATORS OF THE INTEGRATED STRESS PATHWAY (Fri, 10 May 2019)
Provided herein are compounds, compositions, and methods useful for the modulation of elF2B, for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
>> Read More

MODULATORS OF THE INTEGRATED STRESS PATHWAY (Fri, 10 May 2019)
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
>> Read More

MODULATORS OF THE INTEGRATED STRESS PATHWAY (Fri, 10 May 2019)
Provided herein are compounds, compositions, and methods useful for the modulation of elF2B, for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
>> Read More

MODULATORS OF THE INTEGRATED STRESS PATHWAY (Fri, 10 May 2019)
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
>> Read More

MODULATORS OF THE INTEGRATED STRESS PATHWAY (Fri, 10 May 2019)
Provided herein are compounds, compositions, and methods useful for the modulation of elF2B and the integrated stress response (ISR) signaling pathway and for treating related diseases, disorders and conditions.
>> Read More

MODULATORS OF THE INTEGRATED STRESS PATHWAY (Fri, 10 May 2019)
Provided herein are compounds of formula (I) and (II), compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
>> Read More

MODULATORS OF THE INTEGRATED STRESS PATHWAY (Fri, 10 May 2019)
Provided herein are compounds of formula (I), compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions. (Formula I).
>> Read More

MODULATORS OF THE INTEGRATED STRESS PATHWAY (Fri, 10 May 2019)
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
>> Read More

MODULATORS OF THE INTEGRATED STRESS PATHWAY (Fri, 10 May 2019)
Provided herein are compounds of Formula (I) or Formula (II), compositions, and methods there of useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
>> Read More

MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE (Fri, 22 Mar 2019)
The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
>> Read More

MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE (Fri, 22 Feb 2019)
The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
>> Read More

MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE (Fri, 22 Feb 2019)
The present disclosure provides for compounds of formula (I), wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
>> Read More

MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE (Fri, 22 Feb 2019)
The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
>> Read More

MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE (Fri, 22 Feb 2019)
The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
>> Read More

1,2,3,4-SUBSTITUTED QUINOLINE COMPOUNDS AS S1P MODULATORS (Fri, 25 Jan 2019)
The invention relates to 1,2,3,4-substituted quinoline compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
>> Read More

BROMODOMAIN INHIBITORS (Fri, 19 Oct 2018)
Compounds of formula (I), wherein R 1, R 2, R 3, R 5, R 6, R 7, A 1, A 2, A 3, A 4, X 1, and X 2 have any of the values defined in the specification and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS are provided. Pharmaceutical compositions comprising of compounds of formula (I) are also provided.
>> Read More

PROLINE AMIDE COMPOUNDS AND THEIR AZETIDINE ANALOGUES CARRYING A SPECIFICALLY SUBSTITUTED BENZYL RADICAL (Fri, 28 Sep 2018)
The present invention relates to proline amide compounds and their azetidine derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, to a method for preventing or treating conditions and disorders which respond to the modulation of the 5-HT2C receptor, and processes for preparing such compounds and compositions.
>> Read More

MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE (Fri, 31 Aug 2018)
The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention. In one embodiment, the compound is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, (I) wherein A1 is selected from the group consisting of X1, X2, X3, X4; R1, R2A, R2B, R2C, R2D, R3, R4,R5A, R5B, R5C, R5D, R6A, R6B, R6C, R6D, R7, R8, R9, R10, R11, R12, R13, and R14 are as described herein.
>> Read More

MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE (Fri, 31 Aug 2018)
The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention. Other embodiments of the invention include a pharmaceutical composition comprising a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier. In one aspect, the invention provides for compounds of Formula (I) (I) wherein A1 is selected from the group consisting of and R1, R2A, R2B, R2C, R2D, R3, R4, R5A, R5B, R5C, R5D, R6A, R6B, R6C, R6D, R7, R8, R9, R10, R11, R12, R13, and R14 are as defined herein.
>> Read More

DEUTERATED CFTR MODULATORS AND METHODS OF USE (Fri, 29 Jun 2018)
The invention discloses compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, A, R19, R20, and R21 are as defined herein. The present invention relates to deuterated compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
>> Read More